A Quarter of Progress, A Year of Innovation Ahead

Q1 2025 CEO Update

As we close out the first quarter of the year, I want to take a moment to reflect on the progress we’ve made and share our vision for the years ahead.

At Monarch Medical Technologies, we have always prioritized scientific rigor, clinical collaboration, and patient-centered innovation. We call it “Innovation for Purpose”. This quarter was a testament to that philosophy.

Our loyal customers – both new and long-standing, remind us that our competitive advantage is consistently delivering superior patient outcomes.

These outcomes exceed those achieved by traditional (e.g. Sliding Scale), homegrown, and even high-cost computational methods based on simplistic Yale or Bode protocols.

Our success stems from leveraging advanced scientific principles and sophisticated algorithms that account for patient-specific factors – such as renal function – that influence insulin response.

True, lasting innovation is only possible when driven by purpose. That’s why we’ve delivered a sustainable, superior solution for more than a decade.

A Quarter Focused on Research and Clinical Excellence

Over the past few months, our commitment to investing in research and clinical validation has been stronger than ever.

We continued to refine and enhance EndoTool’s patient-specific insulin dosing technology, ensuring it remains at the forefront of glycemic management innovation.

One of the greatest strengths of Monarch is our ability to listen to and collaborate with leading clinical experts.

Our Clinical Advisory Board (CAB) and Nurse Advisory Board (NAB) have been instrumental in shaping our advancements.

Driving Evidence-Based Innovation

Comprised of leading endocrinologists, pulmonologists, and medical researchers, the CAB helps us ensure that EndoTool is aligned with the highest standards of care. Their expertise guides:

• Clinical protocol development, ensuring EndoTool remains in step with the latest evidence.
• Research initiatives, advancing safety and efficacy in insulin dosing.
• Product innovations, to keep Monarch ahead of the curve in glycemic management.

Enhancing the Nursing Experience

The NAB represents frontline nursing professionals from critical care, diabetes management, and nursing informatics, ensuring that EndoTool integrates seamlessly into nursing workflows. Their input has helped us:

• Optimize nursing workflows, improving efficiency and ease of use.
• Refine protocols, ensuring patient safety and adherence to best practices.
• Identify unmet needs, helping us tailor solutions that directly support patient care.

Through regular meetings and continuous collaboration, both boards reinforce our mission to make inpatient insulin dosing safe and more precise for healthcare providers and patients alike.

A Year of Growth and Innovation

As we move forward, 2025 will be a year of strategic growth and technological innovation.

To support this vision, we have expanded our leadership team, bringing in highly experienced professionals with expertise in diabetes care, healthcare technology, and strategic product development.

Their guidance will help us accelerate our focus on AI and cloud-based solutions to enhance clinical decision making and support new therapeutic applications for patient-specific insulin dosing.

With these advancements, we are not just improving EndoTool – we are shaping the future of inpatient glycemic management.

Thank You for Your Trust

We remain committed to delivering inpatient insulin dosing technology, driven by research, validated by clinical experts, and designed for patient care.

We appreciate the trust that hospitals, providers, and partners continue to place in Monarch, and we look forward to another year of progress.